An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
Public ClinicalTrials.gov record NCT00235300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients
Study identification
- NCT ID
- NCT00235300
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 240 participants
Conditions and interventions
Interventions
- Thymoglobulin [Anti-thymocyte Globulin (rabbit)] Biological
- Simulect (basliximab) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2000
- Primary completion
- Mar 31, 2003
- Completion
- May 31, 2005
- Last update posted
- Mar 17, 2015
2000 – 2005
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35296 | — |
| UCLA School of Medicine | Los Angeles | California | 90095 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| Florida Hospital Medical Center and Translife | Orlando | Florida | 32804 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Medical College of Georgia | Augusta | Georgia | 30912 | — |
| Rush University Transplant Program | Chicago | Illinois | 60612 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | — |
| St. Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28232 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00235300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2015 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00235300 live on ClinicalTrials.gov.